ERA - Leading European Nephrology

My ERA Join ERA

Home | ERBP

Bodies: ERBP

8 / 8 results found

SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease

SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease

Speaker
Patrick Mark, United Kingdom

Panellists
Evangelia Dounousi, Greece
Sokratis Stoumpos, United Kingdom

Moderator
Pantelis Sarafidis, Greece

SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease

ERBP

Chronic kidney disease: the missing concept in the 2019 EULAR/ERA-EDTA recommendations for lupus nephritis

July 11, 2023

ERBP

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)

June 24, 2023

ERBP

SGLT2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EuReCa-M and ERBP working groups of ERA

May 25, 2023

ERBP

Atherosclerotic Renovascular Disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH)

May 18, 2023

ERBP

Alignment and Synergy in Long-Term Vision: A Memorandum of Understanding between the European Renal Association and the Kidney Disease Improving Global Outcomes

April 11, 2023

ERBP

A European Renal Best Practice (ERBP) endorsement of ISTH Guidelines for Treatment of Thrombotic Thrombocytopaenic Purpura (TTP) with some refinements for Europe.

February 23, 2023

ERBP

Management of obesity in kidney transplant candidates and recipients

November 12, 2021

DESCaRTES WG